Fetuses Found to Have Elevated Levels of 'Forever Chemicals' in Blood
A recent peer-reviewed study from Mount Sinai has revealed that fetuses likely have significantly higher concentrations of Pfas, commonly known as 'forever chemicals,' in their blood than previously estimated. This research, which analyzed 120 umbilical cord blood samples, challenges existing testing methods and raises concerns about prenatal exposure to these persistent compounds.
Expanded Testing Uncovers Hidden Pfas Compounds
Traditional testing for Pfas in umbilical cord blood typically focuses on a limited set of common compounds, such as Pfoa and Pfos. However, the Mount Sinai study employed a more comprehensive 'non-targeted analysis' that scans for thousands of Pfas variants. This approach identified 42 distinct Pfas compounds across the samples, with total Pfas levels substantially exceeding those detected in earlier assessments.
Shelley Liu, a co-author of the study and associate professor at the Icahn School of Medicine at Mount Sinai, emphasized the significance of these findings. 'Babies are exposed to many more Pfas than we previously thought,' Liu stated. 'This is particularly important to understand because it is a very vulnerable period when fetuses are exposed.'
Health Implications and Regulatory Gaps
Pfas, a class of approximately 15,000 compounds, are widely used to make products resistant to water, stains, and grease. These chemicals have been linked to serious health issues, including:
- Cancer
- Birth defects
- Decreased immunity
- High cholesterol
- Kidney disease
Dubbed 'forever chemicals' due to their inability to break down naturally in the environment, Pfas exposure in fetuses has been associated with higher infant mortality, low birth weight, obesity later in life, and increased risks of neurological and cardiovascular diseases.
While legacy compounds like Pfoa and Pfos have been phased out in recent years, they have been replaced by newer generations of Pfas. Chemical manufacturers often claim these replacements are less toxic, but evidence is frequently lacking. Moreover, Pfas can degrade into new compounds once in the environment or human body, complicating detection efforts.
Regulatory methods for monitoring Pfas in blood, water, and other mediums have struggled to keep pace with these changes. For instance, the US Environmental Protection Agency typically tests water samples for only around 30-40 compounds, despite independent researchers identifying thousands. A 2022 Guardian analysis highlighted that regulators often undercount Pfas levels in water.
Study Methodology and Future Directions
The Mount Sinai study compared umbilical cord blood samples using both traditional analysis and the broader non-targeted approach. As expected, the more comprehensive testing revealed a greater number of Pfas compounds. The EPA recently certified a blood test that checks for 53 compounds, but the Mount Sinai analysis found 31 compounds not included in this test.
Although the study did not directly assess health outcomes, Liu noted that higher Pfas levels in blood are generally correlated with increased health risks. The blood samples were drawn as part of the federal government's Home study, which tracks Pfas exposure and health outcomes over a lifetime. Mount Sinai researchers plan to investigate the health implications further.
David Andrews, acting chief science officer at the Environmental Working Group, commented on the study's implications. 'This paper is a stark reminder of the importance of health-protective regulations and how lax oversight can result in babies being born pre-polluted with harmful chemicals such as Pfas,' Andrews said. He added that the findings suggest harms to babies exposed to Pfas mixtures have likely been underestimated due to measurement limitations.
This research underscores the urgent need for updated regulatory frameworks and more thorough testing to protect fetal health from the pervasive threat of 'forever chemicals.'
